Y-Trap

Executive Summary

Y-Trap is a private biotechnology company pioneering next-generation cancer immunotherapies through the development of novel multispecific antibodies. Unlike traditional checkpoint inhibitors, which primarily block immune checkpoints, Y-Trap's approach reprograms the tumor immune microenvironment to correct immunosuppressive phenotypes. Founded in 2018 and headquartered in San Francisco, the company aims to address limitations of existing immunotherapies by engaging multiple immune pathways simultaneously. While specific pipeline candidates and clinical stages are undisclosed, the company's focus on multispecific antibodies positions it within a rapidly evolving and competitive field. The lack of public funding or valuation data suggests an early-stage profile, typical for companies at the preclinical or early clinical phase. The scientific premise is innovative, but execution risks remain high given the complexity of bispecific and trispecific antibody engineering and the crowded immuno-oncology landscape.

Upcoming Catalysts (preview)

• Q4 2026Publication of preclinical data in a peer-reviewed journal or major conference60% success
• Q2 2027Series A or seed funding round announcement50% success
• Q1 2028First-in-human clinical trial initiation for lead candidate30% success